Kirby McInerney LLP | Financial Litigation Law Firm | <h3 >NeoGenomics, Inc. Investigation</h3 >
This links to the home page
Cases
PRACTICE AREAS

NeoGenomics, Inc. Investigation


The law firm of Kirby McInerney LLP is investigating potential claims against NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). The investigation concerns whether NeoGenomics has violated the federal securities laws and/or engaged in other unlawful business practices.
 
NeoGenomics specializes in cancer genetics testing and information services and aims to provide comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer.
 
On Monday, March 28, 2022, NeoGenomics’ Chief Executive Mark Mallon stepped down as the health-testing company revealed that first-quarter financials will miss guidance and rescinded its forecast for the full year. On this news, the price of NeoGenomics shares declined by $5.30 per share, or approximately 29.8%, from $17.79 per share to close at $12.49 per share on March 29, 2022.
 

NeoGenomics, Inc. Investor Contact Form